GlycoMimetics Inc reports results for the quarter ended in September - Earnings Summary

Crescent Biopharma

09/11/2022 14:33

* GlycoMimetics Inc  GLYC.OQ  reported a quarterly adjusted
loss
of 16 cents​​ per share for the quarter ended in September. The
mean expectation of three analysts for the quarter was for a
loss of 26 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GlycoMimetics Inc's reported EPS for the quarter was a
loss
of 16 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * GlycoMimetics Inc shares had risen by 24.6% this
quarter and
lost 52.3% so far this year.
    * The company reported a quarterly loss of $8.52 million.
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 02:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.26          -0.16          Beat
 Jun. 30 2022      -0.28          -0.25          Beat
 Mar. 31 2022      -0.31          -0.28          Beat
 Dec. 31 2021      -0.34          -0.33          Beat